• Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

  • Jul 31 2024
  • Length: 18 mins
  • Podcast

Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

Listen for free

View show details

  • Summary

  • Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
Show more Show less

What listeners say about Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available